Skip to main content

Table 4 Correlation between AURKA intensity and clinical features based on the published raw data

From: Aurora kinase A (AURKA) promotes the progression and imatinib resistance of advanced gastrointestinal stromal tumors

Parameter Characteristic No. patients (%) AURKA intensity Statistics P value
Location Stomach 40 (66.7) 8.91 ± 1.25  F = 1.923 0.156
Non-stomach 16 (26.7) 9.64 ± 1.55   
Parenteral 4 (6.7) 9.47 ± 1.69   
AFIP risk* High 17 (28.3) 10.2 ± 1.59  F = 8.686 < 0.001
Intermediate 14 (23.3) 9.38 ± 1.43   
Low 16 (26.7) 8.48 ± 0.64   
Very low 13 (21.7) 8.34 ± 0.55   
Local recurrence* No 54 (90.0) 8.83 ± 1.03 t = 7.377 < 0.001
Yes 6 (10.0) 12.0 ± 0.63   
Metastasis* No 45 (75.0) 8.56 ± 0.82 t = 6.921 < 0.001
Yes 15 (25.0) 10.9 ± 1.22   
Mutation* Sensitive 45 (75.0) 8.91 ± 0.18 t = 2.442 0.018
Resistance 15 (25.0) 9.88 ± 0.44   
  1. *P < 0.05 was considered statistically significant